Disease Landscape and Forecast Insights

Treatment of bladder cancer is influenced by a number of factors including disease stage and histology. The swift entry of immune checkpoint inhibitors has transformed the treatment algorithm for…

Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…

Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…

Several new drugs have recently entered the PsA market, including new entries into the biologic disease-modifying antirheumatic drug (bDMARD) and targeted synthetic disease-modifying antirheumatic…

Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…

Acute kidney injury (AKI) is defined as functional or structural abnormalities of the kidneys that cause sudden impairment of fluid homeostasis, resulting in retention of metabolic products over a…

Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…

Patients with osteoporosis are at increased risk of fractures owing to the loss of bone strength, yet diagnosis and drug-treatment rates for this disease are relatively low. The low treatment rates…

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care…

MARKET OUTLOOKThe treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…

MARKET OUTLOOK Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents…

MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years…